Key result
Natalizumab reduces rates of relapse and disease progression in multiple sclerosis, but its use is restricted due to the risk of progressive multifocal leukoencephalopathy.
Why the study?
Does natalizumab improve outcomes in patients with relapsing-remitting multiple sclerosis who have failed first-line treatments?
Case Report (n=1)
Does natalizumab improve outcomes in patients with relapsing-remitting multiple sclerosis who have failed first-line treatments?
Natalizumab is a treatment option for relapsing-remitting multiple sclerosis but its use is restricted due to the risk of progressive multifocal leukoencephalopathy.
Answers are grounded in this paper and cite their sources.
May support use after first-line failure in relapsing-remitting multiple sclerosis; leaves open PML risk stratification in larger cohorts.
A 30-year-old woman with relapsing–remitting multiple sclerosis presents for consideration of treatment with natalizumab after several first-line treatments have failed. Natalizumab has been shown to reduce the rates of relapse and disease progression in multiple sclerosis. However, use of this agent is restricted because of the risk of progressive multifocal leukoencephalopathy, a serious central nervous system disorder.
No takes yet. Share an insight, caveat, or question.
Richard M. Ransohoff (2007) conducted a case report in Relapsing-remitting multiple sclerosis (n=1). Natalizumab was evaluated. Natalizumab reduces rates of relapse and disease progression in multiple sclerosis, but its use is restricted due to the risk of progressive multifocal leukoencephalopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: